📌 The essentials On February 12, 2026, the FDA approved drug labeling changes to six menopausal hormone therapy products, removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from their boxed warnings. This is the first batch of approvals. At the FDA’s request, 29 drug companies have submitted proposed labeling changes, with additional approvals expected as submissions are reviewed. The six products affected: Bijuva (estradiol and progesterone), Divigel (estradiol gel), Cenestin (synthetic conjugated estrogens A), Enjuvia (synthetic conjugated estrogens B), Prometrium (progesterone), and Estring (estradiol vaginal system). What was NOT removed: the boxed warning for endometrial cancer remains on systemic estrogen-alone products. This is a clinically important retained warning that all prescribers and patients should be aware of. Context: the FDA initiated this label review in November 2025 following a comprehensive scientific literature review, an expert advisory panel in July 2025, and a public comment period. The 29-company label update process is ongoing.

Menopausal hormone therapy has had a complicated two decades in American medicine. In the early 2000s, the Women’s Health Initiative (WHI), a landmark landmark trial, reported findings that were widely interpreted as showing hormone therapy increased risks of breast cancer, heart disease, stroke, and blood clots. The FDA added boxed warnings to hormone therapy products reflecting those risks. Prescribing dropped dramatically, and it never fully recovered.

The scientific community has spent years re-examining those findings. The primary methodological critique has been consistent: the average age of WHI participants was 63, more than a decade past the average age of menopause onset. The formulation used (conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin) is not representative of current prescribing, which increasingly favors body-identical hormones. And subsequent analyses specifically in younger women who started HRT closer to menopause onset showed a substantially different risk profile.

On February 12, 2026, the FDA acted on that updated evidence. It approved the removal of cardiovascular disease, breast cancer, and probable dementia risk statements from the boxed warnings of six hormone therapy products. The action is the first step of a broader process affecting 29 drug products.

---

What a Boxed Warning Is and Why Its Removal Matters

A boxed warning is the FDA’s most prominent safety communication on a drug label. It appears inside a bold black border at the top of the prescribing information and is reserved for serious or life-threatening risks. Its presence signals to prescribers that the drug carries risks serious enough to warrant special consideration and monitoring.

For many prescribers and patients, a boxed warning is functionally a deterrent. The presence of a cancer warning or heart disease warning on hormone therapy labels has contributed to underutilization for more than two decades. The utilization gap is stark: in 2020, approximately 41 million U.S. women were between ages 45 and 64, yet only about 2 million women ages 46 to 65 received a hormone therapy prescription. That is roughly 1 in 20.

Removing those specific risk statements from the boxed warning reflects the FDA’s conclusion, after comprehensive scientific review, that the evidence no longer supports placing cardiovascular disease, breast cancer, and probable dementia in the most prominent warning position on the label.

---

What Was Removed and What Was Retained

This distinction is clinically critical and was largely absent from most coverage of this announcement.

Removed from boxed warnings (for the six approved products):

• Risk statements related to cardiovascular disease
• Risk statements related to breast cancer
• Risk statements related to probable dementia

Retained and not changed:

• The boxed warning for endometrial cancer remains on systemic estrogen-alone products. This warning is not being removed because it reflects a well-established, causal biological relationship: unopposed estrogen in women with an intact uterus increases the risk of endometrial hyperplasia and endometrial cancer. This is why women with an intact uterus who use systemic estrogen-alone therapy require concurrent progestogen. This warning is not a legacy artifact of the WHI. It reflects established reproductive endocrinology and has not been reconsidered in this process.
• Contraindications remain in the prescribing information for all updated products, including active arterial thromboembolic disease (stroke, myocardial infarction), known or suspected breast cancer, known or suspected estrogen-dependent neoplasia, undiagnosed abnormal uterine bleeding, active liver dysfunction, and known hypersensitivity.

Why the endometrial cancer warning staying matters Estrogen stimulates growth of the uterine lining. Without progesterone or progestogen to counteract that stimulation, prolonged unopposed estrogen exposure in women with a uterus can cause endometrial hyperplasia and increase the risk of endometrial cancer. This is not a disputed risk. It is a well-characterized biological mechanism that has been known since the 1970s. The current label update specifically preserves this warning for systemic estrogen-alone products (such as estradiol patches, oral estrogens, and estradiol gels like Divigel). Women with an intact uterus who use systemic estrogen therapy must be prescribed a progestogen alongside it. This requirement does not change with the February 2026 label updates.

---

The Scientific Evidence Behind the Label Changes

The FDA’s decision followed a systematic process that included an expert advisory panel in July 2025, a comprehensive literature review, and a public comment period. The relevant evidence base is substantial and has been building for years.

The WHI reanalysis and the timing hypothesis

The Women’s Health Initiative enrolled women with an average age of 63. When researchers reanalyzed the WHI data stratifying by age at enrollment and time since menopause, a different picture emerged. Women who started HRT within 10 years of menopause onset or before age 60 showed different outcomes than those who started more than 10 years post-menopause. This is sometimes called the “timing hypothesis” or “window of opportunity.”

The Kronos Early Estrogen Prevention Study (KEEPS) enrolled women aged 42 to 58 within 36 months of their final menstrual period and found that low-dose oral or transdermal estradiol started early in the menopausal transition did not increase cardiovascular risk over four years.

The Early versus Late Intervention Trial with Estradiol (ELITE) randomized women to estradiol or placebo based on time since menopause (fewer than 6 years, or more than 10 years). It found that estradiol slowed progression of subclinical atherosclerosis in women who started within 6 years of menopause but not in those who started later, directly supporting the timing hypothesis.

The Menopause Society’s 2022 position statement concluded that the benefits of hormone therapy outweigh the risks for most healthy symptomatic women who begin treatment under age 60 or within 10 years of menopause, and that the WHI data should not be applied indiscriminately to all hormone therapy users.

The FDA’s February 2026 label update represents the regulatory translation of this accumulated body of evidence.

What the updated labels say about timing

The FDA’s updated labeling recommendation is to start systemic HRT within 10 years of menopause onset or before age 60. This is not an absolute contraindication for later initiation, but it is a clinical guidance point that the label will now include explicitly.

The benefit claims: what the evidence actually supports

The HHS fact sheet accompanying this announcement cited risk reductions including cardiovascular diseases by up to 50%, Alzheimer’s disease by 35%, and bone fractures by 50 to 60%. These figures come from observational analyses and secondary endpoint analyses from the relevant literature. They represent the upper estimates of potential benefit from studies of women who initiated HRT at younger ages and are not uniformly established as causal effect sizes across all formulations and populations. The fracture reduction data is the most consistently supported. The cardiovascular benefit in the timing window is biologically plausible and supported by the evidence above. The Alzheimer’s protection data is promising but still the subject of ongoing research. The appropriate interpretation of these figures is that they reflect the potential magnitude of benefit in women who use HRT appropriately, not guaranteed outcomes for every individual patient.

---

Which Products Are Affected and Their Updated Labels

The six products in the first batch of approved labeling changes represent all four major categories of menopausal HRT:

Product	Category	Active ingredient	Updated label
Bijuva	Systemic combination (estrogen plus progestogen)	Estradiol and progesterone	Link
Divigel	Systemic estrogen-alone (topical gel)	Estradiol	Link
Cenestin	Systemic estrogen-alone (oral)	Synthetic conjugated estrogens A	Link
Enjuvia	Systemic estrogen-alone (oral)	Synthetic conjugated estrogens B	Link
Prometrium	Systemic progestogen-alone	Progesterone (micronized)	Link
Estring	Topical vaginal estrogen (ring)	Estradiol vaginal system	Link

The remaining 23 drug companies that submitted proposed labeling changes are still in the review process. Their products will be updated as submissions are approved. The FDA’s menopausal hormone therapies updated prescribing information page will track additional products as they are approved.

---

What This Means for Women and Clinicians

For women currently using or considering HRT

The removal of boxed warnings for cardiovascular disease, breast cancer, and probable dementia does not mean these risks are zero. It means the FDA has concluded that the evidence does not support placing them in the most prominent risk-warning position for the indicated population (women using HRT appropriately, typically within 10 years of menopause onset and before age 60).

HRT remains an individualized decision that should account for personal risk factors including:

• Personal or family history of breast cancer
• History of blood clots, stroke, or cardiovascular disease
• Liver disease
• Undiagnosed vaginal bleeding
• Time since menopause and age at initiation

The Menopause Society’s practitioner finder can help identify clinicians with menopause medicine certification who are equipped to discuss the updated evidence and individual risk profiles.

For clinicians

The label changes affect prescribing information and patient counseling conversations. Women who have avoided HRT because of the boxed warnings may now re-engage with the question, and clinicians should be prepared to have evidence-based conversations about individualized benefit-risk assessment. The retained endometrial cancer warning for estrogen-alone products, the continued contraindications, and the timing guidance are all still present in the label and remain clinically operative.

What has not changed

HRT still requires a prescription. Contraindications still apply. The timing guidance (within 10 years of menopause onset or before age 60 for systemic HRT) is a recommendation, not an absolute cutoff. Women with an intact uterus still need progestogen with systemic estrogen. The conversations between clinician and patient remain the appropriate framework for HRT decisions.

For related coverage on how this label change fits into the broader reassessment of hormone therapy in women’s health, see our posts on vaginal estrogen therapy safety in endometrial cancer survivors, hormone therapy underuse in women with premature ovarian insufficiency, and new 2026 cervical cancer screening guidelines allowing self-collection.

---

Sources

FDA press announcement: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA.gov. February 12, 2026.

HHS announcement (November 2025): HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA.gov. November 10, 2025.

HHS fact sheet: FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. HHS.gov. November 10, 2025.

FDA updated prescribing information tracker: Menopausal Hormone Therapies with Updated Prescribing Information. FDA.gov.

Updated label: Bijuva: accessdata.fda.gov.

Updated label: Divigel: accessdata.fda.gov.

Updated label: Cenestin: accessdata.fda.gov.

Updated label: Enjuvia: accessdata.fda.gov.

Updated label: Prometrium: accessdata.fda.gov.

Updated label: Estring: accessdata.fda.gov.

Contemporary OB/GYN coverage: FDA updates labels on multiple menopausal hormone therapies. contemporaryobgyn.net. February 12, 2026.

Pharmacy Times coverage: FDA Approves Drug Labeling Changes to 6 Menopausal Hormone Therapy Products. pharmacytimes.com. 2026.

Prism News coverage: FDA narrows boxed warnings for six menopausal hormone therapies. prismnews.com. February 13, 2026.

KEEPS trial: Harman SM et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005. PMC3678904.

ELITE trial: Hodis HN et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016.

Menopause Society 2022 position statement: The 2022 Menopause Society Position Statement on Hormone Therapy. menopause.org.

WHI background: Women’s Health Initiative. National Heart, Lung, and Blood Institute.

Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, risk factors, and symptom burden.